ADELAIDE, Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. Avance Clinical is taking meetings with biotechs to discuss the benefits of conducting trials in Australia, including no IND requirement and an attractive 43.5% rebate, at Biotech Showcase 2022 via PartneringOne. Connect with the Avance Clinical Team here https://www.avancecro.com/contact-us/ Download the APAC clinical trial advantages report from Frost & Sullivan herehttps://www.avancecro.com/download-apac-clinical-trial-report-frost-sullivan/ Avance Clinical is the Australian-owned CRO
The post Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022 appeared first on Pharma Mirror Magazine.
